share_log

Certara Launches Cloud Platform to Further Unify Its End-to-End Scientific Software Platform

GlobeNewswire ·  Apr 16 08:00

PRINCETON, N.J., April  16, 2024  (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions.

Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results.

"This reusable suite of shared platform services enables us to both integrate with and launch new interoperable software solutions that span our customers' workflows from discovery to submission," said Max Kanevsky, Chief Technology Officer of Certara Data Sciences Software. "Clients want easy-to-use, integrated solutions that speed time to insight for novel drug development problems," said William F. Feehery, CEO of Certara. "Certara Cloud enhances the customer experience for clients that use multiple Certara products."

Certara Cloud delivers value and unique capabilities across several areas of immediate benefit and lays the foundation for future advanced operations, including:

  • Real-time collaboration across internal teams and external partners with reduced friction in deployment, licensing, and technical implementation.

  • Centralized security and IT administration, leveraging Single Sign On and cross-product user management and auditing functions.

  • Best practices documentation and media-rich educational resources from thought leaders spanning all stages of drug development including complimentary access to the gold standard PK/PD e-book, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications.

  • Cross-functional insights and benchmarks for clients, derived from following their drug candidate across its various stops in the Certara ecosystem.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment